Grace Therapeutics, Inc. (GRCE): Cash & Equivalents
$16.98M
As of 2026-03-31
$13.76M
As of 2026-06-30
-15.2%
3-year compound annual growth
-19.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $16.98M | -23.3% | 2026-06-18, Balance as of period end |
| 2025-03-31 | $22.13M | -3.8% | 2026-06-18, Balance as of period end |
| 2024-03-31 | $23.00M | -17.5% | 2025-06-23, Balance as of period end |
| 2023-03-31 | $27.88M | -8.1% | 2024-06-21, Balance as of period end |
| 2022-03-31 | $30.34M | -40.4% | 2023-06-23, Balance as of period end |
| 2021-03-31 | $50.94M | +257.7% | 2022-06-21, Balance as of period end |
| 2020-03-31 | $14.24M | -15.6% | 2021-06-22, Balance as of period end |
| 2019-03-31 | $16.87M | n/a | 2020-06-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | $16.98M | -23.3% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $66.00M | -30.1% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $40.27M | -23.9% |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $57.05M | -48.6% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $4.58M | -47.6% |
| Rallybio Corp (RLYB) | 2025-12-31 | $31.37M | +125.7% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $59.05M | -46.7% |
| Lifevantage Corp (LFVN) | 2025-06-30 | $20.20M | +19.6% |
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $19.94M | -6.6% |
Compare GRCE, CNTX, SPRO, HOWL side by side · Screen every company in Pharmaceutical Preparations ↗